Jacob Soumerai, Md

This study tested a drug called belantamab mafodotin (Blenrep) in 10 people with rare, aggressive lymphomas that had come back or not responded to treatment. The drug is an antibody-drug conjugate designed to target and kill lymphoma cells. The trial was terminated early, so the …